Regeneron Pharmaceuticals/ US75886F1075 /
| 2024-05-03 9:59:55 PM | Chg. +19.15 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 957.51USD | +2.04% | 23,406 Turnover: 22.19 mill. |
-Bid Size: - | -Ask Size: - | 105.45 bill.USD | - | 25.83 |
Assets
|
2010 US GAAP in mill. USD |
2011 US GAAP in mill. USD |
2012 US GAAP in mill. USD |
2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 347.5000 | 368 | 379.9000 | 527 | 974.3090 | ||||||
| Intangible Assets | - | - | - | - | - | ||||||
| Long-Term Investments | - | - | - | - | 460.1540 | ||||||
| Fixed Assets | - | - | - | - | 1,704.3660 | ||||||
| Inventories | 0.0000 | 0.0000 | 0.0000 | 70.4000 | 128.8610 | ||||||
| Accounts Receivable | 81.9000 | 103.1000 | 693.1000 | 891.8000 | 739.3790 | ||||||
| Cash and Cash Equivalents | 112.6000 | 483.6000 | 230.3000 | 535.6000 | 648.7190 | ||||||
| Current Assets | 357.6000 | 665.8000 | 1,206 | 1,796.9000 | 2,167.4610 | ||||||
| Total Assets | 1,089.4000 | 1,323.6000 | 2,080.5000 | 2,951 | 3,871.8270 | ||||||
Liabilities
|
2010 US GAAP in mill. USD |
2011 US GAAP in mill. USD |
2012 US GAAP in mill. USD |
2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 15.6000 | 27.7000 | 38.9000 | 61.9000 | - | ||||||
| Long-term debt | - | - | - | - | 146.7730 | ||||||
| Liabilities to Banks | - | - | - | - | - | ||||||
| Provisions | - | - | - | - | - | ||||||
| Liabilities | 561.6000 | 837.9000 | 835.1000 | 998.9000 | 1,329.5020 | ||||||
| Share Capital | .1000 | .1000 | .1000 | .0990 | .1020 | ||||||
| Total Equity | 527.8000 | 485.7000 | 1,245.4000 | 1,952.1000 | 2,542.3250 | ||||||
| Minority Interests | - | - | - | - | - | ||||||
| Total liabilities equity | 1,089.4000 | 1,323.6000 | 2,080.5000 | 2,951 | 3,871.8270 | ||||||
Income Statement
|
2010 US GAAP in mill. USD |
2011 US GAAP in mill. USD |
2012 US GAAP in mill. USD |
2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 459.1000 | 445.8000 | 1,378.5000 | 2,104.7000 | 2,819.5570 | ||||||
| Depreciation (total) | - | - | - | - | - | ||||||
| Operating Result | -97.5000 | -205.2000 | 457.7000 | 760 | 838.4310 | ||||||
| Interest Income | -9.1000 | -21.3000 | -45.3000 | -46.4000 | -37.3720 | ||||||
| Income Before Taxes | -104.5000 | -222.9000 | 414.4000 | 713.4000 | 775.7470 | ||||||
| Income Taxes | 0.0000 | -1.1000 | -335.8000 | 289 | -427.6730 | ||||||
| Minority Interests Profit | - | - | - | - | - | ||||||
| Net Income | -104.5000 | -221.8000 | 750.3000 | 424.4000 | 348.0740 | ||||||
Per Share
Cash Flow
|
2010 US GAAP in mill. USD |
2011 US GAAP in mill. USD |
2012 US GAAP in mill. USD |
2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | 99.2000 | -141.7000 | -74.6000 | 583.6000 | 743.1570 | ||||||
| Cash Flow from Investing Activities | -437 | 128.5000 | -81.1000 | -355.5000 | -420.7770 | ||||||
| Cash Flow from Financing | 243.3000 | 384.2000 | -97.6000 | 77.1000 | -209.2690 | ||||||
| Decrease / Increase in Cash | -94.5000 | 371 | -253.3000 | 305.3000 | 113.1110 | ||||||
| Employees | 1,395 | 1,704 | 1,950 | 2,340 | 2,925 | ||||||
